1Desai HV, Aronow WS, Peterson SJ, e! al. Cardiac amyIoidosis: approaches to diagnosis and management. [J]Cardiol Bey, 2010,18(1):1-11.
2Goldman L, Ausiello D. Cecil textbook of medicine. [J]Philadelphia: Saunders. 2004 : 171.
3Kyle RA,Gertz MA. Primary systemic amyloidosis:clinical and laboratory in 474 cases. [J]Semin Hematol, 1995, 32:45-59.
4Kholov6 l, Niessen HW. Amyloid in the cardiovascular system:a review. [J] Clin Pat hol, 2005, 58 (2) : 125--133.
5Qu z, Zheng X, Wang SX, et al. Clinical and pathdosical featuresofrenal amyloidceis : an analysis of 32 patients in a single Chinesecentre. [J]Nephrology (Carhon), 2010, 15 (1) :102-107.
6Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus meJlphalan plus dexamethasone for Alamyloidosis. [J]N Engl, 2007, 357: 1083--1093.
